The QualityStocks Daily Thursday, September 28th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(PIXY) $1.0500 +141.38%

SmallCapRelations(GEMZ) $0.0900 +64.84%

Schaeffer's(RAD) $0.5097 +19.01%

The QualityStocks Daily Stock List

Vaccinex (VCNX)

TradersPro, QualityStocks, MarketClub Analysis, StreetInsider, StockMarketWatch, The Stock Dork, Schaeffer's, PennyStockProphet, OTCtipReporter, MarketBeat, InvestorsUnderground and BUYINS.NET reported earlier on Vaccinex (VCNX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vaccinex Inc. (NASDAQ: VCNX) is a clinical-stage biotech firm which is focused on the discovery and development of vaccines and bio-therapeutics that help treat critical conditions and diseases such as neurodegenerative ailments, autoimmune disorders and cancer.

Vaccinex Inc. was founded in 1997 by Deepak Sahasrabudhe and Maurice Zauderer and serves consumers in the United States. The firm is based in Rochester, New York. The company has a clinical trial supply and collaboration agreement with Merck KGaA to test patients with NSCLC using pepinemab combined with a checkpoint inhibitor, avelumab.

The firm’s portfolio includes ActivMAb antibody discovery platform and SEMA4D (semaphoring 4D) antibody platform. The firm’s lead product candidate, pepinemab, has been developed to help treat Alzheimer’s disease, non-small cell lung cancer, melanoma, osteosarcoma and Huntington’s disease.

In addition to this, Vaccinex Inc. is also developing a human antibody dubbed VX5, and CXCL13, to treat MS and other autoimmune diseases. The product is currently in preclinical development. Its other products include VX25, which will be used to stimulate NKT cells for cancer immunotherapy.

The firm recently announced that it would be licensing an antibody discovered in ActivMAb, which has the potential to inhibit tumor growth as seen in animal studies. Vaccinex Inc. which works on alternative treatments of cancer may soon have a breakthrough, thus providing effective treatments to patients who do not respond to current treatments, thereby allowing the company to grow its portfolio and see an increase in their stock prices.

Vaccinex (VCNX), closed Thursday's trading session at $1.51, up 34.8214%, on 4,081,509 volume. The average volume for the last 3 months is 830,245 and the stock's 52-week low/high is $1.07/$12.36.

Soleno Therapeutics (SLNO)

StockMarketWatch, MarketBeat, QualityStocks, TradersPro, StreetInsider, InsiderTrades, TraderPower, Money Morning, Penny Stock 101, PennyStockLocks, Stock Beast, Zacks, StockRockandRoll, TopPennyStockMovers, TradersPro Morning and Schaeffer's reported earlier on Soleno Therapeutics (SLNO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Soleno Therapeutics Inc. (NASDAQ: SLNO) (FRA: 6XC1) is a clinical stage biopharmaceutical firm that is engaged in the development and commercialization of new therapies for the treatment of various rare diseases.

Soleno Therapeutics is headquartered in Redwood City, California and was established on August 25, 1999. Before changing its name to Soleno Therapeutics Inc. in 2017, the firm was known as Capnia Inc.

Soleno Therapeutics is party to a collaboration agreement with Vanderbilt University that entails the discovery and development of next generation K(ATP) activators to treat rare ailments. The firm is focused on the treatment of neurobehavioral and metabolic disorders.

Soleno Therapeutics’ product candidates include an oral tablet to be ingested once a day indicated for the treatment of Prader-Willi Syndrome dubbed DCCR or Diazoxide Choline Controlled-Release tablets. The candidate is currently being assessed for its effectiveness in a phase 3 clinical development program. The firm also provides products like Serenz Nasal Relief, which is a nasal irrigator that uses carbon dioxide to wash nasal passages; NeoPIP Infant Resuscitator, which has been developed to help resuscitate infants and neonates in the clinical environment and the CoSense ETCO end-tidal carbon monoxide (ETCO) monitor. Soleno Therapeutics designed the monitor to measure end-tidal carbon monoxide to help detect fatal rates of hemolysis.

Soleno Therapeutics Inc. recently announced that they would be conducting another clinical trial to support their NDA submission for DCCR to the FDA. This, their CEO said, would ensure that the product, which has shown its potential as an effective and safe treatment option for patients with PWS, is approved for patients as swiftly as possible.

Soleno Therapeutics (SLNO), closed Thursday's trading session at $27.59, up 33.4785%, on 9,079,193 volume. The average volume for the last 3 months is 2.176M and the stock's 52-week low/high is $0.85/$30.30.

Baudax Bio (BXRX)

The Stock Dork, QualityStocks, BUYINS.NET, The Online Investor, StockMarketWatch, MarketBeat, PennyStockScholar, PennyStockProphet, InvestorPlace and Early Bird reported earlier on Baudax Bio (BXRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Baudax Bio Inc. (NASDAQ: BXRX) is a specialty pharmaceutical firm that is engaged in the development and commercialization of products manufactured for acute care settings as well as hospitals.

It has its headquarters in Malvern, Pennsylvania and was founded in 2019. It is focused on advancing non-opioid analgesics. The company’s objective is to bring clinically meaningful therapeutic options to health care providers and patients. The firm has multiple therapeutic candidates across late, mid and early-stage clinical development.

The firm’s product pipeline includes an injectable form of a long-acting preferential COX-2 inhibitor Meloxicam, dubbed ANJESO, which is available in IV form. ANJESO has been indicated for use in adults to help manage moderate to severe pain, either in combination with NSAID analgesics or alone.

Other products in its pipeline include Dexmedetomidine-IN, which is dexmedetomidine in an intranasal formulation and two NMBAs (neuromuscular blocker agents) and related chemical reversal agents. It is also developing a reversal agent that’s specific to its NMBAs, an ultrashort-acting NMBA dubbed RP2000 and an intermediate-acting NMBA termed RP100. The company has successfully concluded phase 3 clinical trials, including a phase 2B program evaluating the effectiveness of ANJESO as well as a large double-blind phase 3 safety trial and two pivotal efficacy trials.

Studies published support the efficacy and safety of ANJESO as well as its tolerability in patients, which suggest that the candidate has a promising role in multimodal analgesic regimens in a clinical setting. The candidate was also approved by the FDA for use, which will not only make it more accessible to patients while meeting an unmet need but also boost investors’ confidence in it, which will be good for the company.

Baudax Bio (BXRX), closed Thursday's trading session at $0.452, up 50.6667%, on 168,816,268 volume. The average volume for the last 3 months is 2,461 and the stock's 52-week low/high is $0.30/$12.24.

Vericity Inc. (VERY)

TradersPro, StreetInsider, MarketClub Analysis, FreeRealTime and BUYINS.NET reported earlier on Vericity Inc. (VERY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vericity Inc. (NASDAQ: VERY) (FRA: 2TE) is a company engaged in the provision of life insurance products for the middle American market.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2013. It operates as part of the insurance-life industry, under the financial services sector. The firm mainly serves consumers in the United States.

The enterprise operates through its subsidiaries; Efinancial LLC (Efinancial) and Fidelity Life Association (Fidelity Life). It operates through Insurance, Agency and Corporate segments. The Insurance segment operates through Fidelity Life, which is involved in the principal business lines of Core Life, Non-Core Life, Closed Block, and annuities and assumed life. It offers term life, accidental death, and final expense products. On the other hand, the Agency segment operates through Efinancial, selling life insurance products for unaffiliated insurance firms through its call center distribution platform, as well as through its independent agents and other marketing organizations. This segment is also involved in the insurance lead sale activities through its eCoverage web presence. The Corporate segment comprises primarily of a small amount of capital required to be maintained for regulatory purposes. It also includes expenses considered to be corporate and not allocated to the Insurance or Agency segments.

The company remains committed to better meeting the significantly unmet need for life insurance and expanding its scale. This may in turn drive its current growth trajectory and help create value for its shareholders.

Vericity Inc. (VERY), closed Thursday's trading session at $6.19, off by 3.2812%, on 1,121 volume. The average volume for the last 3 months is 14,850 and the stock's 52-week low/high is $4.70/$9.2793.

Melkior Resources (MKRIF)

We reported earlier on Melkior Resources (MKRIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Melkior Resources Inc. (OTC: MKRIF) (CVE: MKR) is a junior mining exploration firm that is focused on acquiring and exploring mineral properties in Canada.

The firm has its headquarters in Timmins, Canada and was incorporated in 1986, on August 31st by Norman Farell. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm primarily serves consumers in Canada.

The enterprise mainly explores for gold, zinc and silver deposits, as well as base metals. Its projects include Carscallen, Bristol, White Lake, Maseres, Genex, Val d'Or, Launay and Urban. The Carscallen Project is made up of 320 claim units that cover an area of roughly 47km2. It is located approximately 25km west of the city of Timmins, Ontario. Its White Lake Project is comprised of over 328 contiguous claim units (12,966 acres), located approximately 15km northeast of the Hemlo Gold Mine operated by Barrick Gold Corporation. The Maseres Project is immediately south of Osisko Mining and Goldseek Resources Inc. Its Genex Project is located about 20km west of Timmins, which includes 70 claims, 6 patents and one partial lease totaling 1,616 hectares. The Val-d’Or Property is located over 35km east of Val d’Or and is comprised of 120 claims covering approximately 6,333.04 hectares.

The company remains focused on employing a systematic approach to exploration and focusing efforts on areas with the most potential that can maximize return on shareholder investments.

Melkior Resources (MKRIF), closed Thursday's trading session at $0.0775, up 0.649351%, on 500 volume. The average volume for the last 3 months is 308,982 and the stock's 52-week low/high is $0.0737/$0.182.

Mama's Creations (MAMA)

MarketBeat reported earlier on Mama's Creations (MAMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mama's Creations Inc. (NASDAQ: MAMA) is a company focused on manufacturing and marketing prepared refrigerated foods.

The firm has its headquarters in East Rutherford, New Jersey and was incorporated in 2009, on July 22nd by Daniel Mancini and Daniel Dougherty. Prior to its name change in August 2023, the firm was known as MamaMancini’s Holdings Inc. It operates as part of the packaged foods industry, under the consumer defensive sector. The firm primarily serves consumers in the United States.

The company’s broad product portfolio, which was born from a rich history in Italian foods, comprises of a variety of high quality, fresh, clean and easy to prepare foods to address the needs of both their consumers and retailers. Its vision is to become a one-stop-shop deli solutions platform, leveraging vertical integration and a diverse family of brands to provide a wide array of prepared foods to meet the changing demands of the modern consumer.

The enterprise provides beef and turkey meatballs, meat loaf, chicken, sausage-related products, and pasta entrees; and hot bars, salad bars, prepared foods, sandwich, and cold deli and foods-to-go sections. It sells its products directly to supermarkets, club chains, and mass-market retailers; and food retailers and distributors, as well as through their website. The enterprise’s brands include MamaMancini’s, Creative Salads and The Olive Branch.

The firm, which recently received 3 QVC 2023 Customer Choice Food Awards, remains committed to better meeting consumer needs and extending its consumer reach. This may in turn help generate additional value for its shareholders.

Mama's Creations (MAMA), closed Thursday's trading session at $4.34, off by 1.3636%, on 272,555 volume. The average volume for the last 3 months is 6,646 and the stock's 52-week low/high is $0.9298/$4.70.

Banxa (BNXAF)

We reported earlier on Banxa (BNXAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Banxa Holdings Inc. (OTC: BNXAF) (CVE: BNXA) (FRA: AC00) is a payments service provider for the cryptocurrency exchanges in Europe, North America and Australia.

The firm has its headquarters in Melbourne, Australia and was incorporated in 2020, on December 23rd by Domenic Carosa. It operates as part of the information technology services industry, under the technology sector. The firm serves consumers around the globe.

The company’sgoal is to onboard the general public to digital currency by building a fully compliant payment infrastructure that enables simple and secure conversion of fiat currency to digital currency. Geographically, it generates most of its revenue from Europe.

The enterprise’s principal business activity is being a payment service provider (PSP) and RegTech platform for the digital assets industry. It provides Web3 on-and-off ramp solutions, allowing end users to purchase cryptocurrency and non-fungible tokens (NFTs) using fiat currency, such as credit cards, wire transfers, and local payment options. Its products comprise of On and off Ramp, OpenRamp, NFT checkout, and Corporate Onboarding. Through its platform, it enables global off-ramping of stablecoins via its network of local bank transfers. Its Fiat-to-NFT service enables customers to purchase NFTs directly via its network of payment options. It allows the users' corporate customers to register and make purchases directly using Banxa, enabling single transactions from enterprises, businesses and trusts. Its BanxaPro product is a high-volume cryptocurrency trading service for professional traders and institutions.

The firm, which recently provided a business update, remains focused on advancing its strategy to bolster its overall growth.

Banxa (BNXAF), closed Thursday's trading session at $0.615, up 9.7235%, on 29,802 volume. The average volume for the last 3 months is 178,840 and the stock's 52-week low/high is $0.065/$1.50.

Solidus Communications (SLDC)

We reported earlier on Solidus Communications (SLDC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solidus Communications Inc. (OTC: SLDC) is a company engaged in the provision of collocation, hosting, software development and technology consulting services.

The firm has its headquarters in Ormond Beach, Florida and was incorporated in 2007, on August 10th by William J. Sanchez. Prior to its name change in March 2023, the firm was known as Telco Cuba Inc. It operates as part of the telecom services industry, under the communication services sector. The firm serves consumers around the globe, with a focus on those in the United States.

The company is dedicated to amassing a portfolio of high value companies in the telecom space. It has subsidiaries offering collocation, hosting, software development, and technology consulting services in the South Florida area.

The enterprise provides telecommunication services and equipment, including mobile phones, mobile voice service, Voice over Internet Protocol (VoIP) service, and calling cards. It intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the enterprise is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, it provides technology solutions, which include but are not limited to software and network architecture services, software development, website development, hosting and colocation services, managed network and managed server services, Voice over Internet Protocol (IP) servers and bulk mailing services.

The firm is in the market for technology-oriented acquisitions that offer residual income in the technology services industry. This may bring in additional investments into the firm while also generating shareholder value.

Solidus Communications (SLDC), closed Thursday's trading session at $0.0038, off by 6.1728%, on 20,802 volume. The average volume for the last 3 months is 58.762M and the stock's 52-week low/high is $0.0021/$0.025.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, Trades Of The Day, MarketClub Analysis, MarketBeat, Daily Trade Alert, Kiplinger Today, StocksEarning, The Online Investor, StockEarnings, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, QualityStocks, Zacks, Stock Up Featured, StreetAuthority Daily, Daily Profit, The Wealth Report, Top Pros' Top Picks, SmallCapVoice, Lebed.biz, SeriousTraders, StockMarketWatch, Wall Street Grand, Profit Trends, Early Bird, Money Morning, INO Market Report, Inside Trading, Jim Cramer, CNBC Breaking News, Cannabis Financial Network News, Louis Navellier, BUYINS.NET, StocksToBuyNow, Outsider Club, Trading For Keeps, MarketClub, AllPennyStocks, Beat The Street, Wealth Daily, Cabot Wealth, VectorVest, Trading Concepts, TradersPro, TheTradingReport, Profit Confidential, Stock Gumshoe, Insider Wealth Advice, Investment U, InvestmentHouse, Rick Saddler, Raging Bull All Access, Investors Alley, 24/7 Trader, Money and Markets and Technology Profits Daily reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

California’s cannabis companies are urging Governor Gavin Newsom to reject a recently passed measure aimed at dissuading children from accessing marijuana products. The businesses argue that the bill would result in the prohibition of the current branding of numerous established products while failing to address the persisting issue of the black market.

Last week, the California Assembly passed AB 1207, which effectively bans any packaging or labeling of marijuana products deemed “enticing to minors.” This bill defines such packaging as any promotional material featuring elements such as cartoons, toys, robots, fictional or real humans, animals, fruits, vegetables, or anything else that regulators believe might appeal to individuals under 21 years old.

Supporters of the bill, including youth advocates, argue that it is necessary in light of the recent uptick in cases of children accidentally consuming marijuana products, some of which have been designed to resemble popular snacks and candies.

According to Zack Kaldveer, spokesperson for the California Public Health Institute, there has been a notable increase in child poisonings and hospitalizations due to such accidental exposures. The California Poison Control reported a surge in annual cannabis exposures, with numbers rising from fewer than 200 in 2010 to more than 1,600 in 2020, with nearly one-half of these cases involving children.

However, the vast majority of cannabis advocacy groups are firmly against the bill, fearing it may inadvertently exacerbate public safety issues rather than mitigate them.

Should the bill be enacted, the California Marijuana Industry Association estimates that most marijuana businesses would be burdened with costs ranging from $100,000 to $300,000 to redesign their product labels. Furthermore, industry insiders argue that the bill’s scope is overly broad, targeting benign packaging of established brands while letting illicit operators off the hook.

Critics point out that the illicit market frequently mimics well-known cereal, candy and snack brands — a practice already prohibited in the legal cannabis industry — and that these products are regularly sold to children by black-market operators.

Newsom has already signed three drug policy-related bills during this legislative session without issuing any vetoes. One measure includes provisions that grant immunity to individuals in possession of personal-use quantities of controlled substances if they test them for contaminants such as fentanyl, report positive results to law enforcement and provide details about the source of the substance. The second measure empowers the State Water Board to investigate suspected illegal cannabis cultivators and participate in enforcement actions, while a third measure alters background check requirements for cannabis businesses.

The proposed change to the marijuana-product labeling rules in California could be of great concern to major industry actors such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) since other jurisdictions could follow these extreme restrictions and enact them as well, compelling licensed companies to walk an even tighter rope in a bid to adhere to all the applicable laws in the jurisdictions in which they operate.

Canopy Growth Corp. (CGC), closed Thursday's trading session at $0.8136, off by 8.5843%, on 85,393,482 volume. The average volume for the last 3 months is 573,908 and the stock's 52-week low/high is $0.346/$4.77.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics are projected to enjoy a compound annual growth rate (CAGR) of 55% and achieve a $7.2 billion valuation by 2029. A recent report from data and analytics firm GlobalData revealed that the psychedelic drug market is poised to experience robust growth before the end of the decade thanks to positive developments on the legislative and regulatory side.

The past couple of years have seen an exponential rise in public and scientific psychedelic interest thanks to a plethora of studies associating hallucinogens such as psilocybin, LSD and ayahuasca with significant improvements in mental health. A growing body of research has revealed that psychedelics can offer long-term relief against mental disorders including treatment-resistant depression, post-traumatic stress disorder (PTSD) and eating disorders at relatively small doses and with few side effects.

Compared to traditional antidepressants that require daily use and often have a myriad of adverse side effects, psychedelics are a potential game-changer for psychiatry that could make mental health treatments safer and more effective than they have ever been before. Results from initial studies are so promising that institutional investors and big pharma are already pouring millions of dollars into the research and development of psychedelic-based treatments for several mental health problems.

Psychedelics’ proven effectiveness against conditions such as PTSD and major depressive disorder that so often affect veterans and first responders has garnered the novel drugs plenty of support among the general public and legislators. However, federal prohibition has consistently been a thorn in the side of the nascent psychedelic drug market, making it extremely difficult for scientists to study the potential benefits and risks of psychedelics and hindering extensive research.

While we do know that psychedelics deliver their effects by acting on neural receptors such as serotonin 5-HT2A receptors, a deeper understanding of their underlying biological mechanisms is needed to develop safer and more effective psychedelic-based drugs.

Regulators have also noticed the therapeutic potential of psychedelics and are taking steps to ease psychedelic research and promote further studies. The Federal Drugs Administration (FDA) released draft guidance for running psychedelic-based clinical trials in June, putting psychedelics on track to gaining regulatory acceptance in the country and reaching the mass market.

GlobalData’s pharma analyst Kevin Marcadia predicted that Cybin’s CYB-003, Small Pharma’s SPL-026 and Atai Life Sciences/Otsuka Pharmaceutical’s PCN-101 would be the top psychedelic drugs by 2029 with a market share of 52%. CYB-003 is poised to launch in December 2027 as a treatment for major depressive disorder, PCN-101 will launch in December 2025 and SPL-026 will launch in 2027.

Marcadia noted that the June guidance from the FDA represented the regulatory agency’s willingness to remove the barriers to psychedelic research and could potentially spur further regulatory reforms and accelerate psychedelic drug development. Companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) already have ongoing psychedelics R&D programs and any easing of the unsupportive regulatory climate will only spur them on.

Mind Medicine Inc. (MNMD), closed Thursday's trading session at $3.3, off by 6.25%, on 778,924 volume. The average volume for the last 3 months is 590,822 and the stock's 52-week low/high is $2.12/$5.01.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, GreenCarStocks, Daily Trade Alert, TopPennyStockMovers, The Online Investor, VectorVest, PoliticsAndMyPortfolio, Small Cap Firm, SmallCapVoice, Eagle Financial Publications and Cabot Wealth reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The European Union is poised to set a requirement that e-fuel vehicles sold beyond 2035 be 100% carbon neutral. A draft document revealed that vehicles powered by e-fuels will have to be completely climate neutral in order to be sold in EU member nations. The EU’s current climate policies require that all vehicles sold in the regional bloc from 2035 have zero carbon emissions at the tailpipe.

However, although all EU member nations agreed to the climate policy this year, Germany argued that e-fuel cars should be exempted from the policy banning the sale of new CO2-emitting vehicles from 2035. This policy essentially prohibits the sale of fossil-fuel-powered cars and vehicles that use other fuels but still produce CO2.

Germany’s efforts to exempt e-fuel cars from climate-change requirements bore fruit earlier this year when EU officials agreed to allow the sale of alternative-energy vehicles past 2035 even if they produce emissions. E-fuels are a relatively new entrant into the energy market and are typically created by mixing hydrogen with carbon dioxide.

These e-fuels are burned in combustion engines and release emissions, but supporters of the technology say the e-fuel production process can offset these emissions because it is quite climate neutral. Conversely, opponents say e-fuels are energy inefficient and expensive, while also wasting resources that could have been invested somewhere more worthwhile.

German lawmakers held up legislative processes for an entire month amid intense debate about the merits of exempting e-fuel vehicles. Their victory may be short-lived if a recent draft EU proposal by Brussels requiring that e-fuel cars run entirely on carbon dioxide-neutral fuels becomes law. The proposed rule would be more stringent than the rules governing low-carbon fuels in other climate policies in the region. In contrast, the EU generally allows member nations to use certain fuels even if their use produces emissions as long they can attain 70% carbon emissions savings.

Most international pundits have recognized climate change as a significant threat to humanity, and the global community has begun adopting policies to reduce the impact of climate change and extreme weather. As fossil fuels are among the largest polluters on the globe, these efforts involve reducing the world’s reliance on fossil fuels and transitioning to technologies that run on renewable energy.

This includes replacing fossil-fuel-powered cars with zero-emission electric cars and transitioning from coal and oil-generated electricity to wind and solar power. Given the role transportation plays in producing emissions in the EU, replacing internal combustion engine vehicles with cleaner alternatives by 2035 would put the EU on track to achieving its climate change goals.

As the regulatory frameworks promoting electric vehicles start being implemented, we are likely to see the sales of manufacturers such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) registering a significant uptick as bans on ICE vehicles bite.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Thursday's trading session at $0.656, off by 0.621118%, on 177,635 volume. The average volume for the last 3 months is 904,788 and the stock's 52-week low/high is $0.44/$1.445.

Cresco Labs Inc. (CRLBF)

InvestorPlace, Kiplinger Today, Daily Trade Alert, MarketBeat, QualityStocks, Top Pros' Top Picks, The Street, Cabot Wealth, The Wealth Report, The Online Investor, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, Early Bird, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bipartisan senators led by Senate Majority Leader Chuck Schumer have formally unveiled a revised cannabis banking bill that would grant America’s state-legal cannabis industry access to financial services. Called the Secure and Fair Enforcement Regulation (SAFER) Banking Act, the measure would ensure state-legal cannabis businesses could access bank deposit accounts, insurance, cashless payments and a variety of other financial services that are accessible to businesses in other industries.

The cosponsors for the revised bill include Senators Chuck Schumer, Steve Daines, Jeff Merkley, Kevin Kramer, Cynthia Lummis, Krysten Sinema, Cory Booker, Bob Mendelez and Dan Sullivan. A statement from the cosponsors said the measure would make small businesses and their communities safer by allowing cannabis retailers to use financial services such as bank accounts and business loans. Furthermore, the statement explained that the measure would protect accounts in credit unions or banks from closure by federal banking regulators due to reputational risk.

For most of the state-legal cannabis industry’s existence, federal prohibition has made it nigh impossible for marijuana businesses to access financial services. Because federal law still classifies cannabis as a Schedule I drug with no medical application and potential for abuse, financial institutions shy away from serving businesses in the state-legal cannabis industry to avoid negative consequences from federal regulators.

This has forced many cannabis retailers to operate on a largely cash-only basis, meaning the average cannabis business likely has physical cash stored on its premises during business hours. Since cannabis and cash are highly liquid commodities, cannabis businesses across the country are at risk of theft and have regularly been subjected to violent robberies.  Limited access to financial aid and loans also reduces growth opportunities in the sector and ensures that only those with large capital backing can have even a remote chance of success.

The SAFER Banking Act and its previous iterations were designed to fix this issue by finally allowing banks and other financial institutions to serve state-sanctioned cannabis businesses without the threat of legal consequences by the federal government.

Schumer said in a separate statement that the federal government had punished marijuana users and businesses in the sector “for too long” despite the continued harm it does to the country. The failed war on drugs caused significant long-term damage to communities of color and is now causing harm to the nascent cannabis sector. In many cases, federal cannabis policies have put many cannabis business owners in mortal danger.

A markup of the bill will be presented to the Senate Committee on Banking, Housing and Urban Affairs this week. Schumer also noted that he intended to bring the revised cannabis banking bill to the Senate floor as quickly as possible.

The cannabis industry, including enterprises such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), will be waiting to see if this draft law fares any better than previous attempts to enact marijuana banking reforms at the federal level.

Cresco Labs Inc. (CRLBF), closed Thursday's trading session at $2.02, up 7.4468%, on 819,294 volume. The average volume for the last 3 months is 967,742 and the stock's 52-week low/high is $1.00/$4.20.

The QualityStocks Company Corner

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

A recent University of Pennsylvania study has found that getting rid of the barriers surrounding solid tumors allows T cells to kill cancer cells more effectively. The research indicates that it is possible to make immunotherapies more effective at treating solid tumors such as lung cancer and pancreatic cancer. Immunotherapy is a relatively new type of cancer treatment that involves "training" the immune system to make it more effective at identifying and killing cancerous cells in the body. However, while this treatment has proven to be relatively effective at treating blood cancers, immunotherapies rarely have an impact on solid cancers. Published in the "Nature Communications" journal, the study represents a major breakthrough in cancer treatment research. Given that many more companies such as Renovaro BioSciences Inc. (NASDAQ: RENB) are devoting huge amounts of resources to developing cell and gene therapies for solid tumors, a time could soon come when these types of cancers can also be treated in the same way that blood cancers are treated with immunotherapy.

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.

RENB-DC11

Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Thursday's trading session at $4.07, up 7.1053%, on 111,631 volume. The average volume for the last 3 months is 38,917 and the stock's 52-week low/high is $0.3928/$4.10.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has started a preliminary economic assessment ("PEA") for the Iska Iska silver-tin polymetallic project in the Potosi Department of southwestern Bolivia. According to the company, the PEA will study the inferred mineral resource estimate ("MRE") of 560 million tonnes grading 13.8 g Ag/t, 0.73% Zn and 0.28% Pb in the Polymetallic (Ag-Zn-Pb) Domain and 110 million tonnes grading 0.12% Sn, 14.2 g Ag/t and 0.14% Pb in the Tin Domain (Sn-Ag-Pb). The announcement noted that for the purposes of the PEA, the mineral resources of both domains will be combined although they do not overlap or share resource blocks. Lead consultant for the assessment will be Australia-based Lycopodium, which will provide coordinate the PEA with development of metallurgical flowsheets. The PEA study will include design of tailings and waste dump facilities, mine design and infrastructure, environmental and hydrology studies.

"We are delighted to commence the PEA study on Iska Iska just three years after we began our initial exploration drill program," said Eloro Resources CEO Tom Larsen in the press release. "This is another major step in moving the development of Iska Iska forward. We are also planning additional definition drilling to further expand the higher-grade zones as well as planning to carry out definitive ‘ore-sorting; tests at TOMRA in Germany. We have assembled an excellent team, which has already been onsite this week to kick off preparations for the PEA study. Recent induced polarization/resistivity surveys west of Santa Barbara have outlined several promising drill targets to extend the Tin Domain and initial drill testing is planned on these new targets."

To view the full press release, visit https://ibn.fm/iDwTa

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Thursday's trading session at $1.37, up 4.5802%, on 36,159 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.10/$.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF) today announced that it has successfully completed its carbon storage pilot plant, demonstrating the value of its novel carbon storage process, In-Process Tailings ("IPT") Carbonation. According to the update, the company processed more than 7 tonnes of tailings and confirmed the engineering design parameters for IPT Carbonation for incorporation in the Integrated Feasibility Study ("IFS") expected to be released on Oct. 12, 2023. The pilot plant also was utilized to successfully apply the IPT Carbonation process to material from a third party, demonstrating the potential to commercialize the process for other projects. In addition, a study by a leading strategy house confirms that the Canada Nickel Crawford project could reasonably expect in excess of C$25 per tonne of CO 2 in storage fees from its IPT Carbonation process based on publicly known storage fees and given communicated carbon price and policy status.

"Our successful pilot plant results, coupled with this study, confirm the significant value potential of the company's IPT Carbonation process," said Mark Selby, CEO of Canada Nickel. "The potential demand for more than 20 million tonnes annually of CO 2 storage is well in excess of the 1 million tonne capacity for Crawford, which supports our company's belief that our Timmins Nickel District can anchor a Zero Carbon Industrial Cluster in the Timmins – Cochrane region. The work also supports our belief that the Crawford project can qualify a portion of its capital expenditures to take advantage of the carbon capture and storage refundable tax credits announced by the federal government in its 2022 budget."

To view the full press release, visit https://ibn.fm/OyAWf

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. [Nasdaq: KSCP] ("Knightscope" or the "Company"), a leading developer of autonomous security robots and blue light emergency communication systems, today announces that two additional contracts for its K5 Autonomous Security Robot ("ASR") have been executed as part of a larger master agreement announced earlier this week . Casinos in Shreveport and Bossier City, Louisiana, will each get a K5 and are the first ASR contracts in the State. These two new ASRs bring the total robots under contract to 5, which include deployments in Las Vegas, Nevada; Council Bluffs, Iowa; and Aurora, Illinois. Knightscope ASRs at each location greet guests with a friendly voice while also providing additional eyes and ears for the large human security team. Robots also offer a two-way communication system to enhance the safety of visitors and workers.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $0.7524, up 1.347%, on 1,231,647 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.36/$3.65.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, IBN will leverage its suite of communications solutions to generate greater awareness of SenesTech, a company focused on developing effective pest-control solutions that are grounded in science and proven through field testing. IBN brings an array of communication channels to the new partnership, including an investor-based distribution network of more than 5,000 key syndication outlets, numerous newsletters and social media channels, and targeted wire services as well as blogs and other powerful outreach tools.

"SenesTech's ContraPest(R) has already been shown to reduce rat activity over 90% when added to an existing integrated pest-management program, and the company is committed to making it even more accessible to its growing list of clients," stated IBN director of operations Chris Johnson in the press release. "We're excited to customize our comprehensive suite of corporate communications solutions for SenesTech as it rapidly approaches the anticipated release of a revolutionary soft bait formulation, which is expected to greatly expand its adoption among big box retailers, key e-commerce channels and leading industry pest management professionals."

To view the full press release, visit https://ibn.fm/T1TcS

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Thursday's trading session at $0.4307, up 6.3457%, on 63,824 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3676/$11.20.

Recent News

Prospera Energy Inc. (TSX.V: PEI) (FRA: OF6B) (OTC: GXRFF)

The QualityStocks Daily Newsletter would like to spotlight Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) .

As one of the oil and gas leaders, Canada is the third-largest holder of proven oil reserves in the world; the country's oil and gas sector is not only big but also green, positioning Canada as an energy powerhouse with an eye on a greener future

The sector reported output growth while slashing emissions, standing as a testament that achieving both growth and environmental sustainability is possible

Amid Canada's firm commitment to a greener future, companies like Prospera Energy are set to benefit as the country seizes the opportunity of the burgeoning market while still ensuring sustainability

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a Canadian public oil and gas exploration, exploitation, and development company, remains dedicated to reshaping the future of the oil and gas sector by demonstrating that environmentally responsible production practices can enhance both resource recovery and industry sustainability. After the transformational year in 2022, when the company turned the tide and increased production, revenue, and asset appreciation while lowering liabilities, Prospera appears to be on a hot streak, poised for 2023 record growth. The company has started the execution of Phase 2 in their development plan, which includes increased production in Alberta through medium-oil development and utilization of horizontal well-technology to capture the significant remaining reserves in Saskatchewan.

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. The company uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery.

Prospera is primarily focused on optimizing hydrocarbon recovery from legacy fields through environmentally safe and efficient reservoir development methods and production practices. It is in the midst of a three-stage restructuring process aimed at prioritizing cost effective operations while appreciating production capacity and reducing liabilities.

The company is based in Calgary, Alberta, Canada.

Operations

Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8% of total reserves having been recovered via legacy vertical well technology.

Restructuring Initiative

In 2021, Prospera enacted a top-down reorganization. The early results of these efforts were on display in May 2023, when the company reported a three-fold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations.

Prospera noted in the news release that it has positioned itself in 2023 to execute the second phase of its development plan aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan.

During the company’s investor summit in August 2023, Prospera CEO Samuel David provided more information regarding this three-phase strategy:

Phase I

Prospera completed the first phase of its restructuring by optimizing operations at its existing assets and addressing legacy arrears and non-compliance issues.

At the beginning of this transformation, the company was producing just 80 barrels of oil equivalent (BOE) per day. In Q4 of last year, Prospera peaked at nearly 1,200 BOE per day. Its breakeven is around 500 barrels per day, illustrating the opportunity for free cash flow. This prospect has driven Prospera’s capital development and optimization in recent quarters.

After a temporary slowdown in production due to harsh winter conditions, Prospera is currently producing about 800 BOE per day and anticipates an additional 300-500 barrels of daily production following the completion of ongoing site maintenance work.

This sustained increase has pushed the company’s NPV from roughly $3 million prior to the restructuring efforts to approximately $72 million today.

In an effort to build on this progress and maximize its available resources, Prospera piloted two horizontal reentries to assess a potential horizontal well transformation at its properties.

Phase II

Following up on the optimization efforts of Phase I, Prospera aims to commence a horizontal well transformation at its properties in the coming months. Based on its pilot wells from Phase I, the company has proposed 10 horizontal well locations at its Cuthbert and Heart Hills properties.

Prospera has likewise proposed eight medium light oil direction wells at its Alberta property, and it is exploring strategic acquisitions aimed at expanding its core area and diversifying its product mix.

Other facets of Phase II include piloting an enhanced oil recovery (EOR) application and continuing to execute its liability management goals and ESG initiatives. Prospera has already abandoned 60 vertical wells as part of its three-year LMR plan to reclaim surface land and reduce the environmental footprint of its operations.

Phase III

Beginning next year, Phase III of Prospera’s corporate redevelopment strategy will focus on continuing the company’s horizontal modular development to appreciate production and optimize recovery of remaining reserves. Prospera intends to implement full-scale EOR applications based on the results of its Phase II pilot program, which is forecast to optimize recovery by greater than 10%.

Prospera also intends to continue its acquisition strategy to diversify its product mix. Its goal, as detailed by in August 2023 investor summit, is to attain 50% light oil, 40% heavy oil and 10% gas – all while continuing to eliminate carbon emissions as part of its existing ESG initiatives.

Poised for Growth

Following its transformational efforts in 2022, Prospera is poised to achieve record growth in 2023. The company has forecast significant reductions in production costs through 2024, alongside sizable increases in daily production.

Prospera is currently exploring strategic acquisition targets to potentially increase its production beyond 5,000 BPD while expanding its reserve base to a billion barrels.

Market Opportunity

While the oil and gas industry faces long-term geopolitical and macroeconomic uncertainty, there is a clear trend to secure supply in the short term. According to Deloitte, the global upstream industry ended 2022 with some of the highest free cash flows on record, driving reinvestment in hydrocarbons and overall investment in clean energy.

The Energy Information Administration recently forecast a dip in global oil inventories over each of the next five quarters, placing upward pressure on oil prices. The agency further forecasts a YoY increase in fuel consumption, exacerbating the effects of OPEC+ production cuts that are set to remain in place through 2024.

For Prospera, these forecasts are promising. The company aims to build on its recent financial growth in the coming months (Prospera reported a three-fold YoY increase in revenue to $13.9 million in 2022), hitting a projected $57 million in total revenue by the end of 2024 while working to expand its core area holdings through accretive M&A transactions.

Leadership Team

Prospera is led by a team with extensive, diverse petroleum industry experience spanning both reservoir management and operations of oil and gas assets. The team boasts a proven track record of reorganizing companies, structuring financing arrangements and positioning for growth.

Samuel David is the company’s President and CEO. He brings to Prospera over 32 years of experience in operation, development and management of oil and gas assets and companies. Mr. David holds a B.Sc. in Mechanical Engineering and a B.A. in Economics from the University of Calgary. His background consists of both engineering and executive management experience with majors Petro-Canada, AEC Oil & Gas (now EnCana / Cenovus) and Husky Energy, as well as founding and operating juniors Ventura Energy and First West Petroleum. Mr. David has proven expertise in corporate planning, production, reservoir engineering, depletion strategies, EOR, property evaluations, acquisitions and divestitures.

George Magarian is VP Subsurface for Prospera. He is a professional petroleum geologist (APEGA) with over 36 years’ experience in the Western Canada Sedimentary Basin. After graduating with an Honors B.Sc. degree in Earth Science from the University of Waterloo, Mr. Magarian spearheaded many successful exploration programs, conducted evaluations for improved recovery schemes and assessed/exploited unconventional oil reservoir opportunities. He has held roles of increasing responsibility, from exploration geologist at oil industry major Petro-Canada and intermediates Anderson Exploration and Jordan Petroleum, to geoscience manager and VP exploration at junior companies Ionic Energy, Gentry Resources and Westfire Energy.

Chris Ludtke is the company’s VP Finance & Accounting. He is a high functioning finance leader with extensive expertise in finance, budgets and planning, accounting, economic evaluation, management, governance and sound decision making. Mr. Ludtke has 20 years of experience within the oil and gas, clean energy and renewables industries, including 12+ years working for Husky Energy before moving into an executive role in the junior oil and gas and hydrogen space. He graduated from the University of Lethbridge (Bachelor of Management) and is a Chartered Professional Accountant in the Province of Alberta.

Matthew Kenna is the CFO of Prospera. He has over 30 years’ experience leading organizations and helping them expand, drive efficiencies and grow profitability. Mr. Kenna is a professional accountant (CPA, CMA) and spent 15 years heading up the financial and operating departments at KUDU Industries, where he fostered financing arrangements, client relationships and manufacturing teams to take the organization from $35M to $150M in revenue. He has extensive experience turning companies around, growing them and building efficient organizations.

Prospera Energy Inc. (OTC: GXRFF), closed Thursday's trading session at $0.1, up 6.2699%, on 46,600 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.041/$0.134.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN) (FRA: GTD0).

In June 2023, The Lancet's eClinicalMedicine journal published combined detailed analyses of Clene's Phase 2 RESCUE-ALS study and its open-label extension trial

In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises

As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets

Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the "Small" journal, describes the catalytic mechanism of action of CLNN's investigational drug CNM-Au8(R). "Small" is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled "A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts," the article examines the potential for the novel catalytic mechanism of CNM-Au8 as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases. The article is coauthored by lead investigators at the University of South Carolina and Clene.

According to the announcement, this study suggested that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. The study was conducted by Hui Wang, PhD., a professor at the University of South Carolina, and a group of graduate students. "CNM-Au8 represents a new way to address the multiple assaults on neuronal health that occur during the course of neurodegenerative diseases," said Clene vice president of translational medicine and study coauthor Karen S. Ho, PhD, in the press release. "Its catalytic activity strikes at a core metabolic deficiency and enables neurons to survive and function in a challenging environment that would otherwise lead to cell death. The remarkable promise of CNM-Au8 to address multiple different neurodegenerative diseases using this catalytic mechanism is truly exciting."

To view the full press release, visit https://ibn.fm/FJUIL

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.5, off by 5.303%, on 345,098 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.414/$3.23.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has delivered the first 10 class 3 EV Cab Chassis Truck to Randy Marion Automotive Group; the vehicles are invoiced at $630,000. According to the announcement, these first 10 vehicles are the initial shipment of an order for 1,000 class 3 vehicles, an order worth $63 million; the order was placed in May 2023. The company anticipates delivering an additional 150 EVs to Randy Marion by the end of 2023, with the remainder of the 1,000-vehicle order slated for delivery throughout 2024. Calling the delivery a "watershed moment" for the company, the announcement noted that the Mullen THREE class 3 EV truck was the first vehicle produced, assembled and now delivered by the company. The Mullen THREE is produced in the company's Tunica, Mississippi, facility, which houses Mullen's commercial vehicle assembly for both Class 1 EV Cargo Vans and Class 3 EV Cab Chassis Trucks. "This is a significant point in our evolution as we shift the company from engineering development and engineering approvals to production and vehicle deliveries for our customers," said Mullen CEO and chair David Michery in the press release. "As the Class 3 line is fully operational, production will be increasing month-to-month throughout the next year."

To view the full press release, visit https://ibn.fm/xdI3T

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.4435, off by 7.0231%, on 45,445,224 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3901/$137.25.

Recent News

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia (CSE: API) (OTCQX: APAAF) (FSE: A0I0, A0I0.F, A0I0.MU, A0I0.BE) today provided an update on the progress of its ongoing drilling program to outline the extent of the mineralized zone at Target IV on its PCH Iconic Clay Project in Brazil. The company has processed and sent 2,255 samples for analysis, from both the Reverse Circulation ("RC") and Auger drill programs to date and expects to release results in the near future. "Appia's RC extensive drilling program at Target IV has reached a total of 147 holes, and we have now completed the first phase of the multi-phase drilling initiatives across our +17,000 hectare PCH Ionic Clay project in Goias state, Brazil," said Appia's President Stephen Burega. "Working within a very tight timeline of just 51 days, our Brazilian team oversaw the program and reached an impressive 2,019 meters drilled and assays are now pending. The RC drill program has been augmented by exploratory auger drilling and sampling, along with ground geophysics to enhance our comprehension of the subsurface composition and the potential expansion of the known mineralized area of Target IV."

To view the full press release, visit https://ibn.fm/wTglV

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Thursday's trading session at $0.151, off by 7.4755%, on 186,301 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.10/$0.40.

Recent News

RVL Pharmaceuticals plc (NASDAQ: RVLP)

The QualityStocks Daily Newsletter would like to spotlight RVL Pharmaceuticals plc (NASDAQ: RVLP).

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference

The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults

The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11%

RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the H.C. Wainwright 25th Annual Global Investment Conference. The conference was held virtually and in person on September 11-13, 2023, at the Lotte New York Palace Hotel in New York City.

RVL Pharmaceuticals plc (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults.

UPNEEQ® (RVL-1201) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (FDA) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ® in September 2020 to a limited number of eye care professionals, with commercial operations expanded in 2021 among ophthalmology, optometry, and oculoplastic specialties.

In February 2022, UPNEEQ® was launched into the medical aesthetics market in the United States. Patients can purchase UPNEEQ® from eye care or medical aesthetic professionals, or through RVL Pharmacy LLC, the company’s wholly owned pharmacy. The company plans to promote UPNEEQ® to people with acquired ptosis and those who are bothered by low-lying lids. RVL Pharmaceuticals believes there is a significant commercial opportunity for UPNEEQ®, given the meaningful unmet need for a non-invasive treatment across millions of acquired-ptosis patients in the United States. The company’s near-term focus is to continue the rollout of UPNEEQ® into the medical aesthetics market through its dedicated aesthetics sales force while continuing to support ongoing utilization and expanded penetration of UPNEEQ® in ocular medicine markets.

RVL Pharmaceuticals continues to raise patient and physician awareness of acquired ptosis and UPNEEQ® through medical conferences, HCP and DTC advertising, social media (e.g., Facebook and Instagram), and marketing partnerships.

The company is incorporated in Ireland and headquartered in Bridgewater, New Jersey.

UPNEEQ®

UPNEEQ® is an oxymetazoline hydrochloride ophthalmic solution for the treatment of acquired blepharoptosis, or low-lying eyelid(s), in adults. It is the first and only FDA-approved ophthalmic solution for this indication.

The once-daily UPNEEQ® eye drop has been shown in clinical trials to result in an average one-millimeter lift of the upper eyelid, and to improve superior visual field in patients with a functional deficit. Patients’ eyelids demonstrate lift in as little as five minutes post dose, with the lift effect lasting as long as eight hours. The preservative-free solution is safe and well-tolerated. Trials demonstrated side effects similar to those of placebo.

The active ingredient in UPNEEQ® is oxymetazoline 0.1%, a direct-acting α-adrenergic receptor agonist that targets receptors in the Müller’s muscle, which causes the muscle to contract and lift the upper eyelid. UPNEEQ® delivers eye-opening results for patients along the entire spectrum of age and condition severity.

UPNEEQ’s health care provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

The target patient population comprises adults with droopy or low-lying eyelids, the majority of whom are female. While the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.

Market Opportunity

A survey of eye care providers and medical aesthetics specialists revealed that they believe that approximately half of adult patients visiting their practices are affected by droopy or low-lying eyelids. Further, the company estimates that approximately 60% of adult women self-identify as having some degree of droopy or low-lying eyelids, and a majority of those women indicate that they are bothered by the position of their eyelids.

The global medical aesthetics market is expected to reach a value of $18 billion in 2027, rising at a compound annual growth rate of over 10%, with North America representing the largest share of the global market. Similarly, the global eye care market is expected to reach a value of $86 billion by 2026, rising at a compound annual growth rate of over 6%. An estimated 100 million adults visit an eye care provider each year in the United States alone.

RVL Pharmaceuticals believes the growth in medical aesthetics and eye care markets will be driven by an aging population and increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time. Other contributing factors include rising disposable income globally and in the U.S.; growing awareness, utilization, and acceptance of elective or minimally invasive and non-invasive interventions; and continued innovation and improved accessibility to treatments due to an increase in the number of physicians who offer eye care and medical aesthetics services.

Management Team

Brian Markison is Chairman of the Board and Chief Executive Officer of RVL Pharmaceuticals. He has more than 30 years of operational, marketing, commercial development, and sales experience with international pharmaceutical companies. He previously served as the President and CEO of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company. Before that he was Chairman and CEO of King Pharmaceuticals Inc. He also held various senior leadership positions at Bristol-Myers Squibb. He received a bachelor’s degree from Iona College.

James Schaub is Executive Vice President and Chief Operating Officer of RVL Pharmaceuticals. Prior to that he served as COO of Trigen Laboratories. He previously was Vice President, M&A of Fougera Pharmaceuticals. Before that he spent five years with King Pharmaceuticals. Mr. Schaub holds a bachelor’s degree in economics from Middlebury College and an M.B.A. from Rutgers Business School.

RVL Pharmaceuticals plc (NASDAQ: RVLP), closed Thursday's trading session at $0.0781, off by 2.7397%, on 18,788,323 volume. The average volume for the last 3 months is 3.728M and the stock's 52-week low/high is $0.0755/$2.42.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

Utopia VR

The QualityStocks Daily Newsletter would like to spotlight Utopia VR

Utopia VR is one of the world’s first ‘Metaverse-As-A-Service’ solutions for business. The company’s hosted and managed subscription software provides businesses a low barrier to entry, browser-based, device agnostic platform where they can manage their own private 3D metaverse meeting spaces. Users can host and attend Zoom-like virtual meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way.

Utopia VR has many technology and privacy advantages over solutions built on other metaverse marketplaces such as Horizon Worlds (META) or Decentraland. Utopia VR works on all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

Utopia VR is headquartered in Kelowna, B.C.

Products

Utopia VR’s The Metaverse for Everyone™ is a one-click, web-based, avatar-driven, mobile-friendly audio- and video-conferencing platform that utilizes innovative 3D web technology. Utopia VR’s virtual platform works on digital devices including PCs, mobile phones and VR headsets such as Oculus Quest or HTC Vive. No software or proprietary hardware is needed.

Users navigate through the various VRoom environments by using avatars. Users can walk, talk and sit – just like they do in the real world. A user’s avatar can be controlled with a computer keyboard, smartphone or virtual reality headsets. Text chat, voice and video is ever-present and used to communicate with others in the VRoom. For important meetings and presentations, users can also import audio, video, 2D art and images, animated 3D objects, PDF files and their favorite NFTs by simply dragging and dropping files into a VRoom or pasting a video link from supported media platforms.

Organizations that have an existing website can transition their digital assets, including text, images, video, PDFs, slideshows and more, to VRoom environments with a simple copy and paste. This will allow their customers and audiences to experience their brand in a whole new, immersive environment.
Utopia VR’s mobile app enables users to personalize their own 3D environments and then schedule business meetings or social meetups in seconds through a proprietary link management system. The app is available for iPhone and iPad users. The company’s website mirrors the app, which means users can access Utopia VR directly from a PC, laptop, tablet, or VR headset without downloading the app.

Market Outlook

Regarded as the next iteration of the internet, the metaverse is a virtual space where the physical and digital worlds coexist and interact, encompassing virtual reality, augmented reality, extended reality and mixed reality, as well as making use of artificial intelligence and other technologies.

Data consolidator Statista estimated that the global metaverse market size stood at $38.85 billion in 2021 and projected the market would grow to be worth $47.48 billion in 2022. From there, Statista forecasts the value of the metaverse market will explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period.

The metaverse could create $5 trillion in opportunity by 2030, according to McKinsey & Company.

Management Team

Stuart Gray, President, Co-Founder and director of Utopia VR, has been an officer and director for both private and publicly traded companies and has led public offerings for junior listed companies that have gone on to realize multibillion-dollar market valuations. He previously was a consultant and quarterbacked taking eXp World Holdings Inc. (NASDAQ: EXPI) public. eXp is a disruptive, no bricks and mortar, real estate brokerage firm with 85,000 agents worldwide using its virtual, software-based, metaverse platform for closing transactions, training and events.

Cory Braden, CTO and director of Utopia VR, is a forward-thinking strategic leader with over 20 years of experience in delivering software as a service. Recognized for a positive leadership style and excellent communication skills, he is well-versed in user experience, complex application architectures, cloud infrastructure and management of high-performance teams.

Terry Woloszyn, VP of Sales and Advisory at Utopia VR, brings vast technical and sales experience to the company. Before joining Utopia VR, he conceived and launched a data security startup and graduated from two startup accelerator programs. He has personally raised $20 million in equity venture funding.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.